comparemela.com
Home
Live Updates
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer : comparemela.com
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improvement in progression-free survival with KRAZATI compared to standard of care...
Related Keywords
United States
,
American
,
Bristol Myers Squibb
,
Tony Mok
,
Abderrahim Oukessou
,
Exchange Commission
,
Department Of Clinical Oncology
,
American Society Of Clinical Oncology
,
Linkedin
,
Mirati Therapeutics Inc
,
Instagram
,
Chinese University Of Hong Kong Cu Medicine
,
Twitter
,
Youtube
,
Facebook
,
Drug Administration
,
Blinded Independent Central Review
,
Clinical Oncology
,
Annual Meeting
,
Chinese University
,
Hong Kong
,
Bristol Myers
,
Myers Squibb
,
Mirati Therapeutics
,
Prescribing Information
,
Better Future
,
Private Securities Litigation Reform Act
,
Annual Report
,
Quarterly Reports
,
Current Reports
,
comparemela.com © 2020. All Rights Reserved.